Hypertension Clinical Trial
Official title:
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection
The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
The intermediate stage of the bi-directional cavopulmonary connection (BCPC) in the
management algorithm of single ventricle palliation is a unique and extraordinary
physiologic condition. It places the superior vena caval blood flow into series with the
lungs i.e. pulmonary blood flow is partially dependent on cerebral vascular flow and
resistance. Differential reduction in the resistances of the systemic, cerebral and
pulmonary vascular beds will result in re-equilibrium of relative blood flows which
translate to alterations in arterial oxygen tension and perfusion pressure. This concept is
demonstrated by the differential effects of carbon dioxide (CO2) and oxygen (O2). CO2
vasodilates and oxygen (O2) vasoconstricts the cerebral vascular bed; the opposite is true
in the lungs. Furthermore, studies have demonstrated that arterial CO2 tension (PaCO2) at
hypercarbic levels is favourable to normocarbia in increasing pulmonary, systemic and
cerebral blood flows and reducing systemic vascular resistance in acute post BCPC patients.
Administration of angiotensin-converting enzyme inhibitor (ACEI) and other systemic
vasodilator drugs are well established for treatment of patients with hypertension and
congestive cardiomyopathy in both pediatric and adult populations. Favourable manipulation
of the flow to the different vascular beds has been reported in children with significant
intra-cardiac shunts in which pulmonary blood flow is decreased relative to the increase in
systemic blood flow as a result of reduction of systemic vascular resistance.
Guided by similar principles, ACEI therapy is administered to patients with single ventricle
physiology to redistribute relative blood flows across the pulmonary and systemic vascular
beds. To date, there exists no study examining the hemodynamic effects of ACEI on relative
blood flows in the setting of single ventricle physiology and in particular, no study
demonstrates its benefits. The effects of ACEI are unknown on the equilibrium of relative
cerebral, systemic and pulmonary blood flows in the post-BCPC state. A relative increase in
systemic blood flow, as effected by ACEI, at the expense of cerebral blood flow may
potentially adversely decrease pulmonary blood and ultimately reduce arterial oxygen
tension. On the other hand, some data suggests that ACEI's improve cerebral autoregulation
function; in which drop in blood pressure will signal a vasodilatory response in the
cerebral vascular bed which may be particularly advantageous in BCPC patients.
Enalaprilat is the active diacid of the ACEI enalapril maleate. Doses of 0.01 to 0.06 mg/kg
i.v. have been safely administered in pediatric studies. Onset of action is 15 minutes and
duration of action is up to 12-24 hours. The pharmacokinetics of this drug are ideal for the
purpose of this study. In our institution, all patients undergo routine cardiac
catheterization after the BCPC procedure for hemodynamic assessment and angiography of
cardiac structures to assess for eligibility for the Fontan operation.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |